Wave Life Sciences Past Earnings Performance
Past criteria checks 0/6
Wave Life Sciences has been growing earnings at an average annual rate of 10.4%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 33.7% per year.
Key information
10.4%
Earnings growth rate
32.0%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 33.7% |
Return on equity | -121.1% |
Net Margin | -50.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Wave Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 113 | -58 | 51 | 0 |
30 Sep 23 | 85 | -85 | 51 | 0 |
30 Jun 23 | 37 | -131 | 50 | 0 |
31 Mar 23 | 15 | -151 | 50 | 0 |
31 Dec 22 | 4 | -162 | 51 | 0 |
30 Sep 22 | 4 | -153 | 49 | 0 |
30 Jun 22 | 40 | -120 | 50 | 0 |
31 Mar 22 | 43 | -118 | 48 | 0 |
31 Dec 21 | 41 | -122 | 46 | 0 |
30 Sep 21 | 49 | -116 | 44 | 7 |
30 Jun 21 | 16 | -143 | 40 | 7 |
31 Mar 21 | 16 | -145 | 40 | 7 |
31 Dec 20 | 20 | -150 | 43 | 7 |
30 Sep 20 | 13 | -178 | 47 | 0 |
30 Jun 20 | 13 | -196 | 50 | 0 |
31 Mar 20 | 17 | -197 | 51 | 0 |
31 Dec 19 | 16 | -194 | 49 | 0 |
30 Sep 19 | 17 | -175 | 48 | 0 |
30 Jun 19 | 19 | -162 | 45 | 0 |
31 Mar 19 | 16 | -156 | 42 | 0 |
31 Dec 18 | 14 | -147 | 40 | 0 |
30 Sep 18 | 12 | -140 | 34 | 0 |
30 Jun 18 | 9 | -127 | 31 | 0 |
31 Mar 18 | 5 | -116 | 29 | 0 |
31 Dec 17 | 4 | -102 | 27 | 0 |
30 Sep 17 | 3 | -90 | 25 | 0 |
30 Jun 17 | 3 | -82 | 22 | 0 |
31 Mar 17 | 2 | -69 | 19 | 0 |
31 Dec 16 | 1 | -56 | 16 | 0 |
30 Sep 16 | 1 | -44 | 15 | 0 |
30 Jun 16 | 0 | -31 | 13 | 0 |
31 Mar 16 | 0 | -24 | 12 | 0 |
31 Dec 15 | 0 | -19 | 10 | 0 |
30 Sep 15 | 0 | -14 | 8 | 0 |
30 Jun 15 | 0 | -10 | 6 | 0 |
31 Mar 15 | 0 | -8 | 4 | 0 |
31 Dec 14 | 0 | -5 | 3 | 0 |
Quality Earnings: 1U5 is currently unprofitable.
Growing Profit Margin: 1U5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1U5 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare 1U5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1U5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 1U5 has a negative Return on Equity (-121.07%), as it is currently unprofitable.